<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138914</url>
  </required_header>
  <id_info>
    <org_study_id>2018/2482</org_study_id>
    <nct_id>NCT04138914</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Focal Cryotherapy for Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Focal Cryotherapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of care treatment for prostate cancer confined to the prostate is
      surgical removal or irradiation of the entire prostate gland. This is effective at curing
      cancer but result in damage to critical adjacent structures such as the urinary sphincter
      muscle and erectile nerves resulting in impaired urinary continence and erectile dysfunction.
      The concept of focal therapy is to treat just the dangerous focus of cancer in the prostate
      while monitoring the rest of the gland, thus avoiding impairment of urinary continence and
      erectile function. We aim to evaluate the degree of preservation of continence and erectile
      function and early oncological outcomes in patients undergoing focal therapy of the prostate
      using cold energy or cryo- ablation. In this study, we seek to evaluate patient reported
      outcomes in urinary, sexual, bowel and general health areas at fixed time points after focal
      cryo-ablation in selected patients with low-volume, localized cancer. The primary goal of
      this study is to demonstrate whether there is a deterioration of scores in these health areas
      over 1 year of follow-up. The secondary goal is to measure cancer control at 1 year
      re-biopsy. Further goals include longer follow-up to monitor cancer progression rates and
      impact on patient survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 2041</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in EPIC (Expanded Prostate Composite Index) subdomain score at 1, 3, 6, 12 months compared to baseline</measure>
    <time_frame>1,3,6 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events assessed by the Clavien-Dindo Scale</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infield (focally treated area) and Outfield (untreated area) positive biopsy rate at 12 months</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Local Progression Rate as measured by follow-up mpMRI (multi parametric magnetic resonance imaging)</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Metastatic Rate as measured by Bone Scan, CT or mpMRI</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death Rate</measure>
    <time_frame>up to 10 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focal Cryotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focal Cryotherapy using 2 freeze-thaw cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Focal Cryotherapy</intervention_name>
    <description>Ablation of the cancer focus within the prostate using cryotherapy</description>
    <arm_group_label>Focal Cryotherapy</arm_group_label>
    <other_name>Focal Therapy</other_name>
    <other_name>Focal Cryoablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  PSA (prostate specific antigen) ≤ 20

          -  Biopsy Gleason score ≤ 4+4

          -  mpMRI shows no gross extracapsular extension

          -  mpMRI shows index lesion volume &lt; 3 ml

          -  ≤ 2 biopsy confirmed lesions on mpMRI

        Exclusion criteria:

          -  American Society of Anesthesiologist score &gt;3

          -  Very high grade cancer (Gleason score &gt; 4+4)

          -  &gt;2 index lesions

          -  Multifocal cancer (any other Gleason &gt;3+3 present and/or Gleason 3+3 at &gt; 3 biopsy
             cores at another site) - Not eligible for mpMRI

          -  Not fit for robotic transperineal saturation biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kae Jack Tay, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kae Jack Tay, MBBS</last_name>
    <phone>(65)63214693</phone>
    <email>tay.kae.jack@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>168753</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kae Jack Tay, MBBS</last_name>
      <phone>(65)63214693</phone>
      <email>tay.kae.jack@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.</citation>
    <PMID>28349978</PMID>
  </reference>
  <reference>
    <citation>Tay KJ, Polascik TJ, Elshafei A, Tsivian E, Jones JS. Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. J Endourol. 2017 Jun;31(6):564-571. doi: 10.1089/end.2016.0830.</citation>
    <PMID>28385075</PMID>
  </reference>
  <reference>
    <citation>Tay KJ, Cheng CWS, Lau WKO, Khoo J, Thng CH, Kwek JW. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes. Radiology. 2017 Nov;285(2):620-628. doi: 10.1148/radiol.2017161650. Epub 2017 Jun 26.</citation>
    <PMID>28654336</PMID>
  </reference>
  <reference>
    <citation>Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Polascik TJ. Surveillance after prostate focal therapy. World J Urol. 2019 Mar;37(3):397-407. doi: 10.1007/s00345-018-2363-y. Epub 2018 Jun 9. Review.</citation>
    <PMID>29948045</PMID>
  </reference>
  <reference>
    <citation>Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21.</citation>
    <PMID>22445223</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

